cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29348438.v1
title: Oral tofacitinib for generalized Dowling-Degos disease with refractory pruritus: a case report

description: To evaluate the efficacy and safety of the Janus kinase (JAK) inhibitor tofacitinib in generalized Dowling-Degos disease (DDD) with refractory pruritus and to comparatively analyze its advantages and limitations versus existing therapies. We report a 61-year-old male with a 20-year history of generalized DDD presenting with pruritic erythematous-to-brown papules and macules refractory to conventional therapies. Multimodal diagnostic evaluations, including dermoscopy and histopathology confirmed the diagnosis, with pruritus severity quantified using the Numerical Rating Scale (NRS). The patient was initially treated with oral acitretin (20 mg/day) combined with prednisone (20 mg/day) for 1 month, followed by maintenance monotherapy with tofacitinib (5 mg twice daily). Oral acitretin exacerbated the pruritus. Following transition to tofacitinib, pruritus was improved from a baseline NRS score of 9 to 5–6 within 1 month. At four-month follow-up, pruritus scores further stabilized at 2–3, accompanied by lesion darkening without recurrence. No adverse events occurred. Tofacitinib represents a promising therapeutic option for DDD with refractory pruritus.
DOI: 10.6084/m9.figshare.30705032
title: Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

description: Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD). This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments. This was a post-hoc analysis of a phase III clinical trial of Ivarmacitinib in moderate-to-severe AD (NCT04875169). Subgroup analysis by with (<i>N</i> = 132) or without (<i>N</i> = 204) previous systemic treatments (systemic corticosteroids, biologics, or other immunomodulators) was performed. In patients with previous systemic treatments, Ivarmacitinib 8 mg (<i>n</i> = 34) and 4 mg (<i>n</i> = 53) exhibited higher Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI)-75, EASI-90, and Worst Itch Numeric Rating Scale (WI-NRS) 4 response rates, and a greater reduction in Dermatology Life Quality Index (DLQI) score compared with placebo (<i>n</i> = 45) at most timepoints from W4 to W16. In patients without previous systemic treatments, these outcomes were notably increased in Ivarmacitinib 8 mg (<i>n</i> = 78) and 4 mg (<i>n</i> = 60) versus placebo (<i>n</i> = 66) throughout W4 to W16. The adverse events were generally comparable between Ivarmacitinib and placebo groups, regardless of previous systemic treatments. Ivarmacitinib demonstrates good efficacy and a favorable safety profile in moderate-to-severe AD patients, irrespective of previous systemic treatments.
DOI: 10.6084/m9.figshare.30705032.v1
title: Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

description: Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD). This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments. This was a post-hoc analysis of a phase III clinical trial of Ivarmacitinib in moderate-to-severe AD (NCT04875169). Subgroup analysis by with (<i>N</i> = 132) or without (<i>N</i> = 204) previous systemic treatments (systemic corticosteroids, biologics, or other immunomodulators) was performed. In patients with previous systemic treatments, Ivarmacitinib 8 mg (<i>n</i> = 34) and 4 mg (<i>n</i> = 53) exhibited higher Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI)-75, EASI-90, and Worst Itch Numeric Rating Scale (WI-NRS) 4 response rates, and a greater reduction in Dermatology Life Quality Index (DLQI) score compared with placebo (<i>n</i> = 45) at most timepoints from W4 to W16. In patients without previous systemic treatments, these outcomes were notably increased in Ivarmacitinib 8 mg (<i>n</i> = 78) and 4 mg (<i>n</i> = 60) versus placebo (<i>n</i> = 66) throughout W4 to W16. The adverse events were generally comparable between Ivarmacitinib and placebo groups, regardless of previous systemic treatments. Ivarmacitinib demonstrates good efficacy and a favorable safety profile in moderate-to-severe AD patients, irrespective of previous systemic treatments.
DOI: 10.6092/unibo/amsacta/8677
title: Echocardiography parameters of healthy neonatal foals

description: This dataset includes echocardiographic measurements from healthy Standardbred neonatal foals, comprising age and body weight at examination and measured echocardiographic parameters. Three files are provided: one containing all measured and calculated parameters, and two containing only measured parameters used for inter- and intra-observer variability analyses.
DOI: 10.6084/m9.figshare.30655797
title: An open single-arm clinical study of microneedle radiofrequency technology for addressing abdominal skin laxity in postpartum women

description: Postpartum abdominal skin laxity represents a common yet challenging condition, with increasing demand for effective and safe noninvasive or minimally invasive treatments, such as phototherapy, radiofrequency (RF), and ultrasound, due to their controlled penetration depth and lower risks. Conventional treatments are limited by reason of thermal injury risk and long recovery periods, necessitating safer and more effective interventions. This open-label, single-arm study evaluated bipolar microneedle radiofrequency (MNRF) for treating abdominal skin laxity in 17 postpartum women. Participants received three treatments at 8-week intervals. Assessments included global aesthetic improvement, abdominal circumference (AC), biomechanical properties, and patient satisfaction. Significant improvements were observed in skin elasticity, viscoelasticity, and echo density; AC showed a non-significant reduction trend with notable aesthetic enhancement. Histological analysis in one subject showed increased collagen density and restoration of the dermal-epidermal junction. Eighty percent of the subjects expressed satisfaction during the treatment period, with a subjective comfort score of 2.93 ± 1.29 (0–10) and an overall satisfaction of 2.40 ± 0.88 (0–4), and no serious adverse events occurred. These results indicate that bipolar MNRF is an effective and safe minimally invasive option for improving postpartum abdominal laxity.
DOI: 10.6084/m9.figshare.30655797.v1
title: An open single-arm clinical study of microneedle radiofrequency technology for addressing abdominal skin laxity in postpartum women

description: Postpartum abdominal skin laxity represents a common yet challenging condition, with increasing demand for effective and safe noninvasive or minimally invasive treatments, such as phototherapy, radiofrequency (RF), and ultrasound, due to their controlled penetration depth and lower risks. Conventional treatments are limited by reason of thermal injury risk and long recovery periods, necessitating safer and more effective interventions. This open-label, single-arm study evaluated bipolar microneedle radiofrequency (MNRF) for treating abdominal skin laxity in 17 postpartum women. Participants received three treatments at 8-week intervals. Assessments included global aesthetic improvement, abdominal circumference (AC), biomechanical properties, and patient satisfaction. Significant improvements were observed in skin elasticity, viscoelasticity, and echo density; AC showed a non-significant reduction trend with notable aesthetic enhancement. Histological analysis in one subject showed increased collagen density and restoration of the dermal-epidermal junction. Eighty percent of the subjects expressed satisfaction during the treatment period, with a subjective comfort score of 2.93 ± 1.29 (0–10) and an overall satisfaction of 2.40 ± 0.88 (0–4), and no serious adverse events occurred. These results indicate that bipolar MNRF is an effective and safe minimally invasive option for improving postpartum abdominal laxity.
DOI: 10.6084/m9.figshare.30101374
title: Early itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial

description: Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD). This post hoc analysis evaluated the impact of early itch relief with ivarmacitinib on quality of life (QoL), working productivity, and sleep quality in affected patients. Data from ivarmacitinib treatment groups in a phase III trial (NCT04875169) were analyzed. Patients were classified as early itch responders (EIR; ≥4-point reduction in Worst Itch Numeric Rating Scale at week 4) or non-early itch responders (non-EIR). Outcomes included the Dermatology Life Quality Index (DLQI) total score, DLQI 0/1 response rate, DLQI work/study item, and the Patient-Oriented Eczema Measure (POEM) sleep item. Of 225 patients, 90 were EIR and 135 were non-EIR. The EIR group showed significantly greater improvements in DLQI total score, DLQI 0/1 response rate, and work productivity from week 4 through week 52 compared to the non-EIR group. Sleep disturbance due to itch was also significantly improved in the EIR group from week 4 to week 40, though the difference at week 52 was not statistically significant. Early itch relief with ivarmacitinib showed significant improvements in QoL, sleep, and work productivity in patients with moderate-to-severe AD.
DOI: 10.6084/m9.figshare.30101374.v1
title: Early itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial

description: Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD). This post hoc analysis evaluated the impact of early itch relief with ivarmacitinib on quality of life (QoL), working productivity, and sleep quality in affected patients. Data from ivarmacitinib treatment groups in a phase III trial (NCT04875169) were analyzed. Patients were classified as early itch responders (EIR; ≥4-point reduction in Worst Itch Numeric Rating Scale at week 4) or non-early itch responders (non-EIR). Outcomes included the Dermatology Life Quality Index (DLQI) total score, DLQI 0/1 response rate, DLQI work/study item, and the Patient-Oriented Eczema Measure (POEM) sleep item. Of 225 patients, 90 were EIR and 135 were non-EIR. The EIR group showed significantly greater improvements in DLQI total score, DLQI 0/1 response rate, and work productivity from week 4 through week 52 compared to the non-EIR group. Sleep disturbance due to itch was also significantly improved in the EIR group from week 4 to week 40, though the difference at week 52 was not statistically significant. Early itch relief with ivarmacitinib showed significant improvements in QoL, sleep, and work productivity in patients with moderate-to-severe AD.
DOI: 10.6084/m9.figshare.30530165
title: Comparative efficacy of omalizumab, dupilumab, and remibrutinib in chronic spontaneous urticaria: a network meta-analysis of randomized control trials

description: Chronic spontaneous urticaria (CSU) is a skin condition that significantly impairs quality of life. While omalizumab remains the standard treatment for patients who have failed antihistamines, emerging therapies show promise in randomized control trials (RCTs). This study aims to compare the relative efficacy of omalizumab, dupilumab, and remibrutinib in CSU. Four databases were searched for RCTs evaluating omalizumab (75/150/300 mg Q4W), dupilumab (300 mg Q2W), or remibrutinib (25 mg BID) in CSU. Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), Dermatology Life Quality Index (DLQI; DLQI 0/1), disease control (UAS7 ≤ 6), and symptom remission (UAS7 = 0) were assessed at weeks 12/24. Frequentist random-effects network meta-analysis were conducted in R. Fifteen studies (4,913 patients) were included. Omalizumab 300 mg demonstrated the greatest efficacy in UAS7, ISS7, symptom remission, and disease control at both timepoints. Remibrutinib showed the greatest DLQI improvement and second-highest UAS7 reduction and odds of symptom remission. Dupilumab provided sustained itch relief but delayed efficacy. Lower omalizumab doses lacked durability at 24 weeks. Omalizumab 300 mg, followed by remibrutinib, exhibited the highest effect sizes across major outcomes for CSU. Newer therapies such as remibrutinib and dupilumab appear generally effective, offering promising tools for CSU patients who may not respond to standard treatments. <b>CAPSULE SUMMARY</b>This network meta-analysis compares omalizumab, dupilumab, and remibrutinib in CSU. Omalizumab 300 mg every four weeks consistently showed the greatest efficacy across outcomes. Remibrutinib improved quality of life, while dupilumab primarily reduced itch.Findings support omalizumab as first-line biologic, with remibrutinib and dupilumab as promising alternatives in possibly distinct populations. This network meta-analysis compares omalizumab, dupilumab, and remibrutinib in CSU. Omalizumab 300 mg every four weeks consistently showed the greatest efficacy across outcomes. Remibrutinib improved quality of life, while dupilumab primarily reduced itch. Findings support omalizumab as first-line biologic, with remibrutinib and dupilumab as promising alternatives in possibly distinct populations.
DOI: 10.6084/m9.figshare.30530165.v1
title: Comparative efficacy of omalizumab, dupilumab, and remibrutinib in chronic spontaneous urticaria: a network meta-analysis of randomized control trials

description: Chronic spontaneous urticaria (CSU) is a skin condition that significantly impairs quality of life. While omalizumab remains the standard treatment for patients who have failed antihistamines, emerging therapies show promise in randomized control trials (RCTs). This study aims to compare the relative efficacy of omalizumab, dupilumab, and remibrutinib in CSU. Four databases were searched for RCTs evaluating omalizumab (75/150/300 mg Q4W), dupilumab (300 mg Q2W), or remibrutinib (25 mg BID) in CSU. Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), Dermatology Life Quality Index (DLQI; DLQI 0/1), disease control (UAS7 ≤ 6), and symptom remission (UAS7 = 0) were assessed at weeks 12/24. Frequentist random-effects network meta-analysis were conducted in R. Fifteen studies (4,913 patients) were included. Omalizumab 300 mg demonstrated the greatest efficacy in UAS7, ISS7, symptom remission, and disease control at both timepoints. Remibrutinib showed the greatest DLQI improvement and second-highest UAS7 reduction and odds of symptom remission. Dupilumab provided sustained itch relief but delayed efficacy. Lower omalizumab doses lacked durability at 24 weeks. Omalizumab 300 mg, followed by remibrutinib, exhibited the highest effect sizes across major outcomes for CSU. Newer therapies such as remibrutinib and dupilumab appear generally effective, offering promising tools for CSU patients who may not respond to standard treatments. <b>CAPSULE SUMMARY</b>This network meta-analysis compares omalizumab, dupilumab, and remibrutinib in CSU. Omalizumab 300 mg every four weeks consistently showed the greatest efficacy across outcomes. Remibrutinib improved quality of life, while dupilumab primarily reduced itch.Findings support omalizumab as first-line biologic, with remibrutinib and dupilumab as promising alternatives in possibly distinct populations. This network meta-analysis compares omalizumab, dupilumab, and remibrutinib in CSU. Omalizumab 300 mg every four weeks consistently showed the greatest efficacy across outcomes. Remibrutinib improved quality of life, while dupilumab primarily reduced itch. Findings support omalizumab as first-line biologic, with remibrutinib and dupilumab as promising alternatives in possibly distinct populations.
DOI: 10.60884/qegi6y
title: Catalytic domain of MmChi60 chitinase from Moritella marina

description: This is a deletion mutant of MmChi60 consisting of only the catalytic domain.
DOI: 10.23634/mmu.00634531
title: Barriers and facilitators towards physiotherapists’ use of behaviour change techniques (BCTs) to improve patients’ adherence to treatment

description: Purpose: Patient adherence to physiotherapy treatment recommendations is less than optimal. This can lead to poor outcomes across a range of clinical and service level measures including patient satisfaction, long‐term morbidity and increased prevalence of long‐term conditions. Physiotherapists have been found to only use a small number of behaviour change techniques (BCTs) in consultations, despite evidence that these can help to improve outcomes in a range of domains including adherence. The dataset arose from a project aiming to explore physiotherapists perceived barriers and facilitators to utilising BCTs in clinical practice. Methods: Fourteen qualified physiotherapists recruited from a higher education institution and a national healthcare provider participated in semi‐structured interviews and reflexive thematic analysis was conducted thereafter.
DOI: 10.60884/zrhhp0
title: Data for a crystal structure of human S-adenosyl-L-homocysteine hydrolase complex with adenosine

description: Data for a crystal structure of human S-adenosyl-L-homocysteine hydrolase complex with adenosine. The data was subsequently treated with a The STARANISO Server.
DOI: 10.34810/data2854
title: Cercocebus torquatus 311

description: Skeleton of Cercocebus torquatus 311.
description: IPA, 1.1.0
DOI: 10.15468/dl.gvubru
title: Occurrence Download

description: A dataset containing 12951 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Roadkill"
 ]
}

 The dataset includes 12951 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054386-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ffhz9t
title: Occurrence Download

description: A dataset containing 91 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Cheirotonus peracanus"
 ]
}

 The dataset includes 91 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054387-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.9b8pz2
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "and" : [
 "GadmGid is CHN.28_1",
 "TaxonKey is Astragalus saxorum"
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054388-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.60884/m7larr
title: Raw X-ray diffraction images of a deletion mutant of MmChi60 chitinase

description: Another data set of raw X-ray images for a deletion mutant (catalyutic domain only) of Chi60 chitinase from a psychrophilic bacterium Moritella marina.
DOI: 10.15468/dl.sn6vmh
title: Occurrence Download

description: A dataset containing 6010 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Specimen",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Pastinaca sativa"
 ]
}

 The dataset includes 6010 records from 322 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054389-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25345/c58s4k30t
title: MassIVE MSV000100234 - Protein profile and cytoarchitecture of the primary motor cortex in pigs and wild boars: insights into the effects of domestication
title: Domestication appears to alter the morphology and physiology of the central nervous system. Due to the limited availability of proteomic and cytoarchitectural data for comparing wild and domesticated animals, we performed a comparative analysis of the cytoarchitecture and protein profile of the primary motor cortex (M1) the key structure controlling motor activity in pigs and wild boars to evaluate the effects of domestication. Protein extraction from FFPE stored tissue sections was performed as follows: ten 10 micrometeres thick sections from each cortex area (R and L) both of pig (n 3) and wild boar (n 3) were pooled and deparaffinized in 2-5 changes of xylene for 10 min each. Then the tissues were rehydrated through a series of graded ethanol (absolute two times, 85, 70) for 10 min each. After rehydration, the tissues were resuspended in an extraction buffer of 20 mM Tris-HCl at pH 6 containing 2 SDS and 0.2 M glycine and incubated at 4 C for 1 hour under agitation. The homogenates were sonicated 3 times for 30 sec each, heated at 100 C for 20 min and successively at 60 C for 2 hours under agitation. The crude extracts were clarified by centrifugation at 14000 g for 20 min at 4 C the supernatants transferred to a new tube while the pellet resuspended in extraction buffer at pH 8.8 and incubated at 50 C for 3 hours under agitation. At the end of incubation time the sample was centrifugated at 14000 g for 20 min. The supernatant were pooled and the protein extracts were treated to reduce the content of SDS using the SDSOut precipitation kit following the manufacturer instructions ThermoFisher Scientific. Briefly, 1 volume of SDS Out precipitation reagent was added to 20 volumes of sample. Then the mixture was incubated in ice for 20 min and centrifuged at 10000 g for 10 minutes at room temperature. The supernatant was transferred to a spin cup column and centrifuged for 1 minute at 10000 g to clarify the supernatant. The samples were stored at -80 C until used. The protein content of the extracts was determined by RCDC of Biorad using serum albumin as standard. 50 micrograms of proteins were loaded onto a Nanosep 10-kDa-cutoff filter and trypsin digested according to our routine protocol. Each digested protein sample was analyzed in technical triplicate. Raw data were processed using PEAKS studio Xpro using the correct precursor only option. Spectra were matched against UniProt sus scrofa reviewed and unreviewed database, to which a list of common contaminants was appended.
DOI: 10.15468/dl.r7wb2z
title: Occurrence Download

description: A dataset containing 3968 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Antarctic Jellyfish"
 ]
}

 The dataset includes 3968 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054390-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.60884/hhybfs
title: Deletion mutant CAT-Ig1-CBM of chitinase MmChi60

description: Raw diffraction images for crystal structure with PDB ID 9FBO.
DOI: 10.60884/zq45lg
title: Deletion mutant of MmChi60 chitinase, containing CAT domain only

description: Deletion mutant of MmChi60 chitinase from a psychrophili bacterium Moritella marina, containing the catalytic domain only.